Alpha Teknova, Inc. (TKNO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alpha Teknova, Inc. (TKNO) Healthcare & Pipeline Overview

Alpha Teknova, Inc. is a key player in the life sciences market, offering critical reagents that facilitate the development of biopharmaceutical products, including drug therapies and vaccines, positioning itself as a reliable partner for pharmaceutical and biotechnology companies.

What Is the Investment Thesis for TKNO?

Alpha Teknova, Inc. presents a unique investment thesis driven by its strategic positioning in the growing life sciences market. With a market capitalization of $375M, the company operates in a sector projected to expand significantly, driven by increasing demand for biopharmaceuticals and diagnostics. Key value drivers include the company's diverse product offerings, which cater to various segments within the life sciences market, and its established relationships with pharmaceutical and biotechnology companies. However, the company faces challenges, including a current profit margin of -41.1%, which highlights the need for operational efficiency improvements. The ongoing development of novel vaccines and therapies presents growth catalysts, supported by increasing investments in healthcare innovation. Overall, Alpha Teknova's ability to capitalize on these trends while addressing its financial challenges will be critical for its future performance.

Based on FMP financials and quantitative analysis

TKNO Key Highlights

Market capitalization of $375M indicates a growing presence in the life sciences sector.

• Profit margin of -41.1% reflects current operational challenges that need addressing.
• Gross margin of 33.3% suggests potential for improvement in cost management.
• Beta of 0.33 indicates lower volatility compared to the broader market.
• No dividend yield as the company reinvests in growth and development.

Who Are TKNO's Competitors?

TKNO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TKNO's Key Strengths?

Strong product portfolio catering to diverse life sciences applications.

• Established relationships with key industry players.
• Commitment to quality and regulatory compliance.

What Are TKNO's Weaknesses?

Current negative profit margin indicating operational challenges.

• Limited brand recognition compared to larger competitors.
• Dependence on a narrow range of product offerings.

What Could Drive TKNO Stock Higher?

Launch of new product lines targeting specific therapeutic areas by Q4 2026.

• Strategic partnerships with biotechnology firms to enhance product offerings.
• Investment in research and development to drive innovation and improve product quality.

What Are the Key Risks for TKNO?

Negative return on equity (-24.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory changes affecting product approvals and market access.
• Competitive pressures from larger companies in the life sciences sector.
• Fluctuations in demand for biopharmaceutical products impacting revenue.

What Are the Growth Opportunities for TKNO?

• Expansion into Emerging Markets: Alpha Teknova has the potential to expand its operations into emerging markets, where demand for biopharmaceuticals is rapidly increasing. The global biopharmaceutical market is expected to grow significantly, with emerging economies contributing to a projected CAGR of 10% over the next five years. By establishing a presence in these markets, Alpha Teknova can tap into new customer segments and drive revenue growth.
• Development of New Product Lines: The company can leverage its existing expertise to develop new product lines tailored to specific therapeutic areas, such as oncology or rare diseases. By diversifying its product offerings, Alpha Teknova can enhance its competitive advantage and meet the evolving needs of its clients.
• Partnerships with Biotech Firms: Collaborating with biotechnology firms can provide Alpha Teknova with access to innovative technologies and expand its product portfolio. Strategic partnerships can facilitate the development of cutting-edge reagents that address specific research needs. The increasing focus on personalized medicine and targeted therapies presents an opportunity for Alpha Teknova to position itself as a leading provider of specialized reagents in this niche.
• Investment in R&D: Increasing investment in research and development can lead to the creation of innovative products that meet emerging market demands. The life sciences sector is characterized by rapid advancements, and companies that prioritize R&D are better positioned to capture market opportunities. Alpha Teknova's commitment to R&D can enhance its product offerings and strengthen its market position.
• Adoption of Automation Technologies: Implementing automation technologies in production processes can improve efficiency and reduce costs. As the demand for biopharmaceuticals continues to rise, companies that can streamline their operations will have a competitive edge. By investing in automation, Alpha Teknova can enhance its operational efficiency and improve its profit margins.

What Threats Does TKNO Face?

• Intense competition from larger, established players in the industry.
• Regulatory changes that could impact product development timelines.
• Market volatility affecting funding for research and development.

What Are TKNO's Competitive Advantages?

• Established reputation for quality and reliability in the life sciences sector.
• Diverse product offerings that cater to various research needs.
• Strong relationships with key players in the pharmaceutical and biotechnology industries.
• Expertise in regulatory compliance and product development.

What Does TKNO Do?

Alpha Teknova, Inc., founded in 1996 and headquartered in Hollister, California, is a prominent provider of critical reagents for the life sciences market. The company has evolved significantly since its inception, focusing on enabling the discovery, development, and production of biopharmaceutical products. Alpha Teknova's product portfolio includes pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements, and molecular biology reagents for sample manipulation, resuspension, and purification. These products are essential for pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. With a workforce of 173 employees, Alpha Teknova has carved out a niche in the healthcare sector, addressing the growing demand for biopharmaceuticals and diagnostics. The company's commitment to quality and innovation has positioned it as a trusted partner in the life sciences industry, enabling its clients to advance their research and product development efforts.

What Products and Services Does TKNO Offer?

• Provide critical reagents for the life sciences market.
• Enable the discovery and development of biopharmaceutical products.
• Offer pre-poured media plates for cell growth and cloning.
• Supply liquid cell culture media and supplements for cellular expansion.
• Deliver molecular biology reagents for sample manipulation and purification.
• Serve pharmaceutical and biotechnology companies, as well as academic institutions.

How Does TKNO Make Money?

• Generate revenue through the sale of reagents and media products.
• Serve a diverse customer base, including pharmaceutical companies and research institutions.
• Focus on high-quality products that meet regulatory standards.
• Leverage partnerships with contract development organizations for expanded market reach.

What Industry Does TKNO Operate In?

The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing robust growth, driven by increasing demand for innovative therapies and diagnostics. The global market for biopharmaceuticals is projected to reach approximately $500 billion by 2027, with a CAGR of around 8.5%. Alpha Teknova, Inc. operates within this dynamic landscape, catering to pharmaceutical and biotechnology companies that are increasingly focused on developing novel drug therapies and vaccines. The competitive landscape includes various established players, but Alpha Teknova's specialized focus on critical reagents positions it favorably to capture market share in this expanding sector.

Who Are TKNO's Key Customers?

• Pharmaceutical companies developing new drug therapies.
• Biotechnology firms focused on innovative treatments.
• Contract development and manufacturing organizations.
• In vitro diagnostic franchises requiring specialized reagents.
• Academic and government research institutions conducting life sciences research.

Wall Street analysts project Alpha Teknova, Inc. revenue of about $45.2M for fiscal 2026, with EPS near $-0.31. The estimate reflects 5 contributing analysts.

Alpha Teknova, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.7% above estimates on average.

Alpha Teknova, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.09 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Alpha Teknova, Inc. stands at -24.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.9%, the inverse of the P/E and a quick read on earnings relative to price.

Alpha Teknova, Inc. (TKNO) Valuation Context

Valued at $375M, TKNO is classified as a small-cap stock. Relative to its peer group, TKNO's quantitative score of 31/100 is below the peer average of 62/100.

TKNO Revenue & Earnings Trend

In Q2 2026, TKNO generated $12.2M in top-line revenue, marking a sequential increase of 10.0%. The company recorded a net loss of $3.2M, with diluted EPS of $-0.06. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, TKNO averaged $-0.08 in diluted EPS.

Company Profile

Alpha Teknova, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hollister, US. The company is led by CEO Stephen Gunstream. TKNO has traded publicly since 2021.

TKNO Financials

TKNO Latest News

TKNO Analyst Consensus

TKNO MoonshotScore

Common Questions About TKNO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources